Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 2008

View Archived Issues

Privigen pharmacokinetics and high infusion rate tolerability studied

New therapeutic options for hepatitis C described in recent patent literature

Recent patents report novel therapeutic agents for neurological disorders

VIA Pharmaceuticals completes enrollment for phase II carotid endarterectomy study

Seattle Genetics begins phase I trial of SGN-33 plus Revlimid in MDS patients

Tripep presents preliminary results from the ongoing ChronVac-C study

EpiCept announces EMEA opinion on Ceplene in AML

Cell Therapeutics completes enrollment for pixantrone phase III EXTEND trial in NHL

Recent Surface Logix patent imparts new treatment option for cardiovascular disorders

Abbott and Takeda to conclude TAP joint venture

IgG-hydrolyzing enzyme shows promise against autoimmune diseases

Neoprobe reports final phase II results with Lymphoseek

Japanese registration study of Soliris completes enrollment

Novel pandemic influenza vaccine effective against H7N7 virus

New phase Ib trial evaluates NPI-2358 for NSCLC

Amrubicin receives FDA orphan drug designation for small cell lung cancer

Novel alphav integrin inhibitor profiled at Johnson & Johnson

Anesiva initiates phase III Adlea trial for postsurgical pain

Array BioPharma files IND for ARRY-614 and initiates phase I clinical trial

Anacor announces positive results from phase IIa trial of AN-2728 in psoriasis patients

DiaMedica enrolls first patient in phase II human clinical trial for DM-83

Neuropharm commences phase II NPL-2009 trial in Fragile X syndrome

Rilonacept available in U.S. for cryopyrin-associated periodic syndromes

Single dose of Iomai patch with H5N1 flu vaccine achieves protective levels

Statistical significance not shown on primary endpoint in SinuNase lavage trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...